Your AI-Trained Oncology Knowledge Connection!

Miranda Lankas

Articles

Ra-223 Improves Outcomes in Prostate Cancer With Bone Metastases

February 18th 2023

Investigators observe low rates of treatment discontinuation and adverse effects with radium-223 as treatment for castration-resistant prostate cancer and bone metastases.

Darolutamide produces a lower rate of discontinuation compared with enzalutamide or apalutamide among patients with non-metastatic, castration-resistant prostate cancer.

Outcomes Improve With Darolutamide Vs Enzalutamide or Apalutamide in nmCRPC

Miranda Lankas

February 16th 2023

Darolutamide produces a lower rate of discontinuation compared with enzalutamide or apalutamide among patients with non-metastatic, castration-resistant prostate cancer.

$Treatment with ibermodide on its own or with anti-CD20 antibodies was well tolerated and demonstrated encouraging responses among patients with relapsed or refractory lymphoma.$

Iberdomide ± Anti-CD20 Therapy Yields Promising Responses in Relapsed/Refractory Lymphoma

Miranda Lankas

December 11th 2022

Treatment with ibermodide on its own or with anti-CD20 antibodies was well tolerated and demonstrated encouraging responses among patients with relapsed or refractory lymphoma.

Pre- and postmenopausal women with breast cancer may experience cognitive impairment with chemotherapy and endocrine therapy, which may return to baseline after 36 months.

Chemotherapy Plus Endocrine Therapy May Confer Further Cognitive Impairment vs. Endocrine Therapy Alone for Breast Cancer Regardless of Menopausal Status

Miranda Lankas

December 7th 2022

Pre- and postmenopausal women with breast cancer may experience cognitive impairment with chemotherapy and endocrine therapy, which may return to baseline after 36 months.

Two-Year KEYNOTE-365 Update Continues to Show Promise of Pembrolizumab Plus Abiraterone in mCRPC Naïve to Chemo

Miranda Lankas

September 11th 2022

Antitumor activity and safety of pembrolizumab plus abiraterone acetate appears to be sustained in chemotherapy-naïve castration-resistant prostate cancer.